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Background: Alternative methods are being sought to measure the potency of influenza vaccines. Label-free
technologies that do not require the use of hemagglutinin (HA)-specific antisera are particularly attractive as the
preparation of antiserum delays availability of potency reagents. The objective of these experiments was to evaluate
the use of a Corning Epic® label-free method to quantify functional influenza hemagglutinin in rHA preparations.
The method was optimized to quantify recombinant HA (rHA) of B/Brisbane/60/2008 (B/BR/08). Fetuin was immobilized
onto plates and the change in wavelength of refracted light measured using an Enspire (Perkin Elmer) instrument.
Results: The change in wavelength measured in response to addition of rHA of B/BR/08 was proportional to its
concentration and was optimal in the presence of native rHA conformations. However, the assay was strain-dependent
and did not correlate with HAU measured using turkey red blood cells.
Conclusions: The Corning Epic® label-free method is suitable for quantifying the native forms of rHA for B/BR/08 and
A/Brisbane/59/2007 (H1N1) and A/Hangxhou/3/2013 (H7N9). This method is a useful tool for research purposes but
further investigation is needed to identify suitable glycoproteins to use as ligands that allow quantification of HAs from
a broader range of virus strains.
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The potency of influenza vaccines is currently measured
by single radial immunodiffusion (SRID) assay [1]. In
this method, antigenically-intact antigen passively dif-
fuses through agar containing monospecific sheep anti-
bodies until a critical concentration is reached at which
a precipitant forms. The precipitant is stained and the
diameter of the zone measured to quantify the amount
of antigen. SRID is suitable as a potency assay because it
clearly distinguishes between antigen that induces hemag-
glutination inhibiting (HAI) antibodies and denatured
antigen that induces poor HAI titers, however, the anti-
serum needed for this assay can take many weeks to pro-
duce, particularly when there are difficulties in purifying
the HA immunogen. Since this bottleneck could impact
timely availability of seasonal and pandemic influenza vac-
cines, alternative potency assays that do not require the
use of antisera are being sought [2].* Correspondence: Maryna.Eichelberger@fda.hhs.gov
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article, unless otherwise stated.Label-free biosensing technologies with optical detec-
tion platforms, such as surface plasmon resonance
(SPR), bio-layer interferometry and Corning’s Epic® tech-
nology, have been used to quantify and determine avidity
of many biomolecular interactions [3-6]. In most in-
stances, the interactions between small molecules are in-
vestigated to elucidate relative binding of ligands and
receptors or to identify inhibitors of these interactions,
although the Epic® technology is also used to identify
mass distribution within cells [4]. The ease of measuring
interactions of the native molecules without the use of
labeled antigen-specific antibodies or other staining
techniques, make label-free systems ideal for also inves-
tigating functional interactions between large multimeric
glycoproteins and cellular receptors.
The trimeric form of HA that is required to induce
functional antibodies is also the form needed to bind sialic
acid-containing receptors [7,8]. Schofield and Dimmock
reported the use of SPR to measure the interaction be-
tween whole influenza virus and antibody [9] and Hidari
et al., quantified the functional receptor binding property
of HA using ganglioside-coated chips [10]. Others haveed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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using chips coated with large glycoproteins such as
fetuin as well as chemically synthesized biotinylated
multivalent glycans [11]. Since the ability of HA to bind
to receptors requires it to have native trimeric conform-
ation, and the native structure of HA corresponds to the
antigenic form needed to induce HA inhibiting anti-
bodies, SPR assays have been designed to measure influ-
enza vaccine potency [12].
Like SPR, the Corning Epic® technology is a label-free
technology but it differs from SPR in that the Epic® reac-
tion does not take place under flow conditions and the
read-out is different. Epic® technology employs reson-
ance wave gating to measure the change in wavelength
of refracted light rather than a change in reflected light
energy that is absorbed by a gold sensor. The Enspire
Multimode plate reader (Perkin Elmer, Waltham, MA) is
a benchtop multimode instrument that includes the
Corning Epic® label-free technology which allows meas-
urement of changes within a cell as well as measurement
of biochemical interactions. We previously demonstrated
that influenza infection of Madin-Darby canine kidney
cells resulted in a signal measured by Epic®, providing a
potential high throughput tool to screen for influenza
antivirals [13]. Since this technology also has capacity to
record changes due to binding events, this report exploresFigure 1 Steps in the Epic® assay for quantification of recombinant H
light wavelength; addition of HA and final read of refracted light wavelength.
picometers (pm).its use for quantifying the interaction between recombin-
ant HA (rHA) and receptors present on a large glycopro-
tein, fetuin.
The ability of Epic® label-free technology to quantify
the native form of rHA was tested by measuring its
interaction with fetuin. Since HA binding depends on
the presence of sialic acid, specificity was demonstrated
through the use of asialofetuin as a control. Binding of a
number of different rHAs from seasonal and pandemic
viruses was examined, demonstrating that while the
assay is suitable for quantifying some rHAs, the HAs of
several influenza viruses had no (or little) reactivity with
fetuin.
Results and discussion
Optimization of conditions for quantitation of HA-receptor
binding by label-free Epic®
The steps conducted to quantify ligand (rHA) with cap-
acity to bind receptor (sialic acid containing carbohy-
drates on fetuin) are shown in Figure 1: (i) fetuin
immobilization step: this is the chemical conjugation of
the receptor-containing glycoprotein to pre-activated
plates; (ii) wash step: following wash and equilibration in
the ligand buffer, the plate is read to establish a baseline
reading; (iii) HA binding step: the ligand (rHA) is added
and the wavelength of refracted light is measured by aA. Immobilization of fetuin; wash step and baseline read of refracted
The response is measured as the difference in wavelength, measured in
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fetuin and an internal control sensor located in a portion
of the well that has no capacity to immobilize fetuin.
The difference in wavelength (measured in picometers
(pm)) is reported as the response.
To identify the optimal concentration and pH for
fetuin immobilization in the first assay step, various
fetuin dilutions (150, 50 and 5 μg/ml) were prepared in
20 mM sodium acetate pH 4.5, 5.0 and 5.5. The change
in wavelength measured after immobilization was pro-
portional to the ligand concentration and was greatest in
20 mM sodium acetate pH 4.5 (Figure 2a). Similar sig-
nals (change in wavelength of ~2000 pm) were obtained
with asialofetuin. After washing the plate immobilized
with 150 μg/ml fetuin or asialofetuin, the response de-
creased (Figure 2b) indicating that this concentration
was in excess of the amount required for maximal chem-
ical conjugation. Responses of ~2000 pm are generally
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Figure 2 Determination of optimal conditions for fetuin
immobilization. (a) Immobilization of different fetuin concentrations in
different pH solutions shows maximum immobilization with 150 μg/ml
at pH 4.5; (b) Baseline read of fetuin and asialofetuin after 2 hr and
24 hr immobilization are similar; baseline read immediately after
washing wells (0 hr) or after washing and 2 hr equilibration (soak step)
were similar. The wells that were washed contained fetuin/asialofetuin
immobilized for 24 hrs.response obtained with fetuin/asialofetuin was consid-
ered adequate for further experiments.
The remaining assay steps were conducted following
the manufacturer’s guidance as described in the Methods
section, with a baseline wavelength reading recorded
after 4 hr equilibration of the fetuin-immobilized plate
in the ligand buffer (PBS, pH 7.4). Serial dilutions of
rHA of B/Brisbane/60/2008 (B/BR/08, Protein Sciences,
Meriden, CT) were added to quadruplicate wells con-
taining fetuin immobilized at various concentrations.
The wavelength of refracted light was read soon after
the addition of rHA and over 30 min at 2 minute inter-
vals because it was expected that equilibrium (and there-
fore maximum signal) may not be reached immediately.
The instrument reported the difference in wavelength
from the sensor in the portion of the well containing
immobilized fetuin and the internal control sensor with-
out immobilized fetuin. As shown for wells containing
immobilized fetuin at 150 μg/ml, the change in wave-
length (response) increased over time when 5, 10 and
20 μg/ml rHA was added, however the differences were
fairly proportional over time suggesting that the re-
sponse measured immediately after addition of rHA
would give similar results to responses measured after
the longest time interval tested (Figure 3). The difference
in response observed by addition of increasing amounts
of rHA even at the initial reading was indicative that
there was significant rHA binding to fetuin in a dose-
dependent manner by the time the plate was placed in
the reader. The response did not increase over time with
2.5 μg/ml rHA indicating that at this low concentration
high avidity interactions between rHA and fetuin were
complete by the time the plate was put in the reader.
Additional experiments were conducted in which the re-
sponse was measured after a longer period (Additional
file 1: Figure S1a-d); the signal due to rHA binding in-
creased slightly with time, but the difference was smallFigure 3 Response measured after addition of increasing
concentrations of rHA increases with time. rHA of B/BR/08 was
added to wells containing immobilized fetuin and change in
wavelength read at 2 min intervals over a 30 min time period. The
greatest difference in response to different rHA concentrations was
observed at 30 min.
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of rHA prior to measuring the response.
The response measured by Epic® label-free assay is
specific for rHA binding to fetuin
Initial experiments were confounded by results showing
responses after adding rHA to wells that did not contain
fetuin (wells without immobilized protein). Obtaining a
signal that was clearly non-specific in empty wells em-
phasized the importance of comparing changes in wave-
length for wells containing immobilized receptor and a
suitable control glycoprotein. Since HA binds to α2-3
and α2-6 sialylated glycoproteins we tested asialofetuin
as a negative control. When asialofetuin and fetuin were
added to chemically-activated plates at the same concen-
tration, the signal obtained was similar, indicating that
they achieved a comparable degree of immobilization
(Figure 2b). Incubation of rHA in wells containing immo-
bilized asialofetuin resulted in minimal changes in wave-
length (response) compared to the response observed in
wells containing immobilized fetuin (Figure 4a-e and
Additional file 1: Figure S1 and Additional file 2: Figure S2).
This result demonstrates that the response measured
when rHA was added to fetuin-immobilized wells was
indeed due to specific binding of rHA to sialic acid-
containing receptors. Asialofetuin was therefore used as
negative control in all experiments.
To verify that the response measured was not the re-
sult of rHA chemically reacting with the plate (becoming
immobilized to wells), the chemical reaction was pre-
vented by treatment of the wells with 200 mM ethanol-
amine before addition of rHA. This treatment reduced
the binding of HA to fetuin (Additional file 2: Figure S2),
suggesting that it had a detrimental impact on the recep-
tor structure. Blocking the chemically-reactive sites in
empty wells did not eliminate the response (Figure 4a),
supporting the hypothesis that rHA was not reacting with
the plate. The change in wavelength following addition of
rHA to empty wells was most likely an indication of differ-
ences in refractive index of the solution with increasing
rHA concentration. Since blocking the chemically-reactive
groups in each well did not benefit the measurement of
the specific response and specificity of the response is
demonstrated in each assay by inclusion of asialofetuin as
control, the blocking step was omitted from the general
protocol.
To evaluate whether the signal could be improved by
removing unbound rHA and to confirm that the signal
was indeed due to binding of rHA to receptors on
fetuin, the plate was washed after addition of rHA.
Washing the plate did reduce the response to some de-
gree (Figure 4d), suggesting that some rHA interactions
with fetuin had low avidity, however the signal was pri-
marily retained. Since the response to asialofetuin servedas a negative control, a wash step was not warranted for
routine experiments.
To investigate whether the signal could be increased
by using fetuin of human origin, the response was mea-
sured in wells containing immobilized human recombin-
ant fetuin A (Sigma, St Louis, MO). This recombinant was
purified from a mammalian (HEK293 cells) expression
system. Due to the expense of this product, a low concen-
tration was immobilized onto the plate. There was good
sensitivity in measuring a response of rHA binding to hu-
man fetuin (response observed even with 2.5 μg/ml rHA),
however the signal was significantly less than the response
measured for rHA binding to immobilized bovine fetuin
(Figure 4b). Further experiments therefore continued to
measure rHA binding to bovine fetuin.
Quantification of rHA in the Epic® label-free assay is strain
dependent
Influenza vaccine potency assays should ideally be gener-
ally applicable so that the same method can be used to
quantify antigenic forms of rHA from both influenza A
and B viruses. To determine whether the conditions estab-
lished for quantifying the rHA of B/BR/08 were applicable
also to other influenza B viruses and influenza A H1N1,
H5N1 and H7N9 viruses, the change in wavelength was
measured after adding rHA from a variety of strains to
fetuin and asialofetuin-immobilized wells. To demonstrate
that the rHAs retained native conformation, we deter-
mined hemagglutination units (HAU) using turkey red
blood cells. The rHA of B/BR/08, B/Wisconsin/1/2010,
A/Brisbane/59/07 (H1N1) and A/Vietnam/1203/2004
(H5N1) had ~1024 HAU/μg; while the rHA of A/
Hangzhou/3/2013 (H7N9) and A/Anhui/1/2013 (H7N9)
had only 32 and 4 HAU/μg, respectively. The low level of
agglutination by H7 proteins may indicate low binding
avidity to receptors on turkey red blood cells rather than
evidence of HA denaturation. Addition of each of the rHA
to bovine fetuin-immobilized wells did not yield a uniform
response; the greatest response was observed with rHA
from B/BR/08, with ~140 pm at 20 μg/ml; the response
measured after addition of rHA from A/Brisbane/59/2007
(H1N1) was less, with ~80 pm at 20 μg/ml (Figure 5). Re-
sponses did not reflect HAU and were not uniform for
each type/subtype of virus; for example, the response to
rHA of B/Wisconsin/1/2010 was minimal while the rHA
of B/BR/08 resulted in reproducible dose-dependent re-
sponses. Also, even though the HAU of the rHA prepar-
ation of A/Hangzhou/3/2013 (H7N9) was low, there was a
measurable response (~80 pm at 20 μg/ml).
The Epic® label-free assay quantifies functional rHA of
B/BR/08 over a range suitable for potency testing
Since potency test results should be a measure of protein
antigenic form, experiments were designed to evaluate




























































































































Figure 4 Specificity of the Epic® response. (a) Addition of
increasing rHA concentrations to empty wells (green line) or wells
containing immobilized bovine fetuin (red line), or asialofetuin (blue
line); (b) Addition of rHA to wells containing immobilized human
fetuin (purple line), asialofetuin (blue line) or bovine fetuin (red line).
Human fetuin and asialofetuin were immobilized at 20 μg/ml;
bovine fetuin was immobilized at 150 μg/ml; (c) Addition of native
rHA (green line) or rHA that had been heated at 95°C for 5 min (red
line) to fetuin immobilized wells; (d) Response of increasing rHA
concentrations added to empty wells (green line) or wells containing
immobilized bovine fetuin (red line) or asialofetuin (blue line) after a
wash and equilibration step; (e) Determination of the linear working
rHA concentration range. rHA of B/BR/08 was added to wells
containing immobilized fetuin (red line) or asialofetuin (green line) at 5,
10, 40, 80 and 160 μg/ml. In all experiments except those using human
fetuin, bovine fetuin and asiaolofetuin were immobilized at 150 μg/ml
under optimal conditions. In experiments using human fetuin,
immobilization was performed with glycoproteins at 20 μg/ml.
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tive and denatured rHA. Red blood cell (RBC) agglutin-
ation provides evidence that rHA is in its native trimeric
form [14], and therefore the response for rHA of B/BR/
08 that has measurable HAU was compared to the re-
sponse measured for the same rHA preparation that had
been heated to 95°C for 5 min and no longer aggluti-
nated RBC. The HAU for each preparation was 2048
and 0 respectively. Titration of each rHA preparation
showed that the response was greatest when the native
structure was present, although rHA did retain some
ability to interact with fetuin after heat denaturation
(Figure 4c). Given that several rHAs did not bind to
fetuin (Figure 5), the Epic® response is unlikely to be due
to a non-specific interaction between HA and fetuin. In-
stead, the response observed with heat-treated B/BR/08
may indicate that trimeric forms of rHA that can bind
fetuin but are not in sufficient quantity to agglutinate
RBC, remain in the preparation. Unfortunately, the
amount of rHA available was too little to evaluate the ex-
tent of denaturation by independent methods. Fluores-
cence spectral analysis of HA of a different influenza B
virus showed that incubation at 60°C for 7 days resulted in
partial denaturation [15], suggesting the feasibility of
retaining some HA with ability to bind receptors after
5 minutes of heating at 95°C. Additional immunogenicity
or SRID assays are needed to establish whether this is in-
deed the case. Nevertheless, the results show that an opti-
mal Epic® response is obtained when functional HA is
used in the assay, and suggests that the Epic® assay may be
suitable for determining the potency of this rHA.
It is important that a reasonable range of HA concentra-
tions can be quantified in any new potency assay. Since
Epic® does not discriminate between influenza A subtypes,
nor influenza types A and B, this assay would only be use-
ful for determining the potency of monovalent vaccines or
monovalent bulk lots. Titration of B/BR/08 rHA on
Figure 5 Epic® response is strain-dependent. The response was measured after addition of increasing concentrations of rHA from different
influenza A and B strains. The ability of each rHA to agglutinate turkey red blood cells is reflected in the HAU provided after each strain name:
B/Wisconsin/1/2010 (1024 HAU/μg), B/BR/08 (2048 HAU/μg), A/Brisbane/59/2007 (H1N1) (2048 HAU/μg), A/Vietnam/1203/2004 (H5N1) (1024
HAU/μg), A/Anhui/1/2013 (H7N9) (4 HAU/μg) and A/Hangzhou/2013 (H7N9) (32HAU/μg). The assays used bovine fetuin immobilized under
optimal conditions at 150 μg/ml. The results of binding to asialofetuin were all negative (no response after addition of rHA).
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rHA concentrations >40 μg/ml (Figure 4e), but that there
is good linearity of the response with increasing concen-
trations between 2.5-20 μg/ml. These results suggest that
the concentration of native rHA in unknown samples or
the stability of a rHA preparation could be measured in an
Epic® assay in which a standard curve of the response is
generated for a reference rHA preparation between 2.5 –
20 μg/ml; the concentration of an unknown sample would
then be calculated from this standard curve after measur-
ing the response at several sample dilutions.
Application of Epic® label-free quantification to research
Our results suggest that the Epic® label-free method using
fetuin-immobilized plates is suitable for quantifying the
native trimeric form of rHA of B/BR/08, A/Brisbane/59/
07 (H1N1) and A/Hangzhou/3/2013 (H7N9). It may also
be suitable for the rHAs of strains that were not included
in this study. Our experience shows the importance of
including immobilized asialofetuin as a negative control
to demonstrate specificity of the reaction in each assay.
In addition, controls such as heat-denatured rHA should
be included to claim conformation-dependence of the
response.
The Epic® assay described in this report is somewhat
more sensitive than the traditional SRID potency assay;
the limit of detection (LOD) of Epic® is approximately
2.5 μg/ml (Figure 3, and Additional file 1: Figure S1 and
Additional file 2: Figure S2) and the LOD of SRID is ap-
proximately 8–10 μg/ml [16,17]. Although this would
allow potency testing at the level needed for current vac-
cine formulations, adjuvanted influenza vaccines that are
dose-sparing are being developed and therefore there is
a need for more sensitive potency assays. ELISAs that
use HA-specific monoclonal antibodies to capture anti-
gen have excellent sensitivity and range (this depends on
monoclonal antibody and antigen, but can be used to
quantify as little as 26 ng HA/ml [16]). ELISAs in which
glycans are used to capture HA before addition ofmonoclonal antibodies to detect the bound HA are also
very sensitive (reported as low as 100 ng HA/ml [18]).
SPR methods that report a signal based on binding to
sialylated glycoproteins have similar a LOD that is simi-
lar to that of the Epic® assay [19], however when syn-
thetic α2-3, or α2-6 sialic acid glyans are used in SPR,
the higher affinity interactions appear to increase assay
sensitivity; as a little as 0.33 μg HA/ml can be quantified
in these assays that have excellent dynamic range [12].
While the use of subtype-specific antisera allow SRID
and ELISAs to quantify HA of a specific virus strain
even when it is mixed with other HA subtypes in a triva-
lent or quadrivalent influenza vaccine formulation [16,20],
Epic® and SPR assays that are antibody-independent do
not discriminate between HA strains [12]. The latter as-
says are therefore only useful for determining the potency
of monovalent bulk material or HA content of monovalent
vaccines. While the ability to measure potency of multiva-
lent formulations is an advantage of antibody-dependent
assays, the low throughput of SRID assays make it cum-
bersome to perform large number of assays on a single
day, whereas ELISA and Epic® assays that are conducted
in a plate format are easy to perform using multichannel
pipettes and automated plate readers to easily quantify
HA in large numbers of samples.
The inability of the current Epic® assay to consistently
measure responses for different rHAs suggests that the
current assay is best suited to quantify rHAs for re-
search purposes and not for general potency testing of
vaccines. The current results align with those obtained
using fetuin as a ligand in SPR that indicate this glyco-
protein does not provide receptors to allow quantifica-
tion of HA from all influenza viruses. While short
synthetic glycoforms with α2-3 and α2-6 sialic acids are
suitable ligands to measure potency of HA in vaccines
by SPR [12], short glycans did not immobilize efficiently
to the chemically-activated plates used for Epic® analysis
(results not shown). Further testing is needed to identify
glycoproteins that can be used to quantify HAs from a
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method.
Conclusions
In this report we describe the optimization of an Epic®
label-free assay to quantify the native form of rHA of
B/BR/08. Immobilized bovine fetuin provides a source of
receptors to which functional HA binds; wells contain-
ing immobilized asialofetuin are used as a negative con-
trol. Further experiments are needed to determine the
comparability of results measured by Epic® for this anti-
gen and the standard influenza SRID potency assay. The
specificity of rHA from different influenza viruses is not
uniform for fetuin and therefore broader application of
the Epic® assay will require additional testing to identify
immobilized substrates to which HA from a broad range
of influenza viruses can bind.
Methods
Reagents
rHAs of influenza A (H1N1 and H5N1) and B viruses
were purchased from Protein Science Inc (Meriden, CT)
and rHAs of influenza A H7N9 viruses were purchased
from Sino Biological (Beijing, China). Bovine and human
fetuin, asialofetuin and all other chemicals were pur-
chased from Sigma (St Louis, MO).
Measurement of hemagglutination units (HAU)
rHA was serially diluted in PBS in a 96 well round bot-
tom plate. An equal volume (50 μl) of 0.5% turkey red
blood cells was added to each well, mixed gently and
allowed to settle for 45 min at room temperature. The
lowest concentration of rHA that resulted in agglutin-
ation was recorded as one HAU.
EPIC® assay for determination of functional rHA
concentration
The assay steps are shown in Figure 1. Epic® plates (384
well) that were chemically activated to allow protein
immobilization were purchased from Perkin Elmer
(Waltham, MA). Fetuin and asialofetuin were immobi-
lized by adding 15 μl of ligand (150 μg/ml) in 20 mM so-
dium acetate pH 4.5 using a multi-channel pipette and
incubating at room temperature for 1 hr. Initial experi-
ments used plates that had been stored overnight at 4°C
however this additional incubation was not necessary to
achieve optimal immobilization. In some experiments
the microplates were blocked from further chemical re-
actions by incubation with 200 mM ethanolamine in
150 mM borate buffer (pH9.2) for 15 minutes. Plates
were then washed three times by applying 25 μl assay
buffer (PBS, pH 7.4). A final volume of 15 μL assay buf-
fer was added and any potential air bubbles removed by
centrifugation of the plate (400 rpm x 1 min). The plateswere equilibrated by incubating at room temperature for
4 hr. The change in signal due to immobilization was re-
corded by comparing wavelength of light refracted from
the immobilized surface and a reference surface within the
same well on an Enspire® multimode plate reader (Perkin
Elmer). Serial dilutions of rHA (15 μl) in dilution buffer
were then added to quadruplicate wells and the change in
wavelength recorded 15 times at 2 min intervals.
Additional files
Additional file 1: The label-free binding response does not require
extensive incubation after addition of rHA to fetuin-immobilized
wells. After a wash and soak step, rHA was added to wells containing
immobilized fetuin or asialofetuin and the change in wavelength from
baseline read immediately (0 hr) and 1, 2 and 3 hrs later. Results are
shown as the average of duplicate wells; standard deviation is shown by
a cross-hatch bar.
Additional file 2: The binding response is impeded if chemically-
reactive sites are blocked after fetuin-immobilization. Response of
rHA binding to immobilized fetuin (red line) or asialofetuin (blue line)
was measured following (A) the usual protocol (no chemical blocking) or
(B) treatment of the plate with 200 mM ethanolamine in borate buffer,
pH 9.5, after the immobilization step (blocking). Results are shown as the
average of duplicate wells; standard deviation is shown by a cross-hatch
bar.
Abbreviations
HA: Hemagglutinin; HAI: Hemagglutination inhibition/inhibiting;
pm: Picometers; rHA: Recombinant hemagglutinin; SRID: Single radial
immunodiffusion; SPR: Surface plasmon resonance.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LJ designed and performed experiments and analyzed results, MCE
contributed to the design of experiments and interpretation of results. LJ
and MCE both contributed to writing of the manuscript. Both authors read
and approved the final manuscript.
Acknowledgements
We thank Hana Golding and Surender Khurana for helpful discussion and are
indebted to Carl Apgar, Paige Derr, Heidi Morgan and Frauke Haenel for
guidance in assay design and interpretation of results. This project was
funded by BARDA.
Received: 18 December 2014 Accepted: 14 February 2015
References
1. Williams MS, Mayner RE, Daniel NJ, Phelan MA, Rastogi SC, Bozeman FM,
et al. New developments in the measurement of the hemagglutinin
content of influenza virus vaccines by single-radial-immunodiffusion. J Biol
Stand. 1980;8:289–96.
2. Hardy S, Eichelberger M, Griffiths E, Weir JP, Wood D, Alfonso C. Confronting
the next pandemic–workshop on lessons learned from potency testing of
pandemic (H1N1) 2009 influenza vaccines and considerations for future
potency tests, Ottawa, Canada, July 27–29, 2010. Influenza Other Respir
Viruses. 2011;5:438–42.
3. Cooper MA. Label-free screening of bio-molecular interactions. Anal Bioanal
Chem. 2003;377:834–42.
4. Fang Y. Label-free cell-based assays with optical biosensors in drug discovery.
Assay Drug Dev Technol. 2006;4:583–95.
5. Naik S, Brock S, Akkaladevi N, Tally J, McGinn-Straub W, Zhang N, et al.
Monitoring the kinetics of the pH-driven transition of the anthrax toxin
Jiang and Eichelberger Biological Procedures Online  (2015) 17:7 Page 8 of 8prepore to the pore by biolayer interferometry and surface plasmon
resonance. Biochemistry. 2013;52:6335–47.
6. Sun H, Wei Y, Deng H, Xiong Q, Li M, Lahiri J, et al. Label-free cell
phenotypic profiling decodes the composition and signaling of an
endogenous ATP-sensitive potassium channel. Sci Rep. 2014;4:4934.
7. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, et al.
Properly folded bacterially expressed H1N1 hemagglutinin globular head
and ectodomain vaccines protect ferrets against H1N1 pandemic influenza
virus. PLoS One. 2010;5:e11548.
8. Magadan JG, Khurana S, Das SR, Frank GM, Stevens J, Golding H, et al.
Influenza A virus hemagglutinin trimerization completes monomer folding
and antigenicity. J Virol. 2013;87:9742–53.
9. Schofield DJ, Stephenson JR, Dimmock NJ. Variations in the neutralizing and
haemagglutination-inhibiting activities of five influenza A virus-specific IgGs
and their antibody fragments. J Gen Virol. 1997;78(Pt 10):2431–9.
10. Hidari KI, Shimada S, Suzuki Y, Suzuki T. Binding kinetics of influenza viruses
to sialic acid-containing carbohydrates. Glycoconj J. 2007;24:583–90.
11. Suenaga E, Mizuno H, Penmetcha KK. Monitoring influenza hemagglutinin
and glycan interactions using surface plasmon resonance. Biosens
Bioelectron. 2012;32:195–201.
12. Khurana S, King LR, Manischewitz J, Coyle EM, Golding H. Novel antibody-
independent receptor-binding SPR-based assay for rapid measurement of
influenza vaccine potency. Vaccine. 2014;32:2188–97.
13. Wu M, Long S, Frutos AG, Eichelberger M, Li M, Fang Y. Interrogation of
phosphor-specific interaction on a high-throughput label-free optical
biosensor system-Epic system. J Recept Signal Transduct Res. 2009;29:202–10.
14. Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, et al.
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of
oligomerization, hemagglutination, and cross-protective immunity in ferrets.
J Virol. 2011;85:1246–56.
15. Luykx DM, Casteleijn MG, Jiskoot W, Westdijk J, Jongen PM. Physicochemical
studies on the stability of influenza haemagglutinin in vaccine bulk material.
Eur J Pharm Sci. 2004;23:65–75.
16. Bodle J, Verity EE, Ong C, Vandenberg K, Shaw R, Barr IG, et al. Development
of an enzyme-linked immunoassay for the quantitation of influenza
haemagglutinin: an alternative method to single radial immunodiffusion.
Influenza Other Respir Viruses. 2013;7:191–200.
17. Eichelberger SL, Sultana I, Gao J, Getie-Kebtie M, Alterman M, Eichelberger
MC. Potency under pressure: the impact of hydrostatic pressure on
antigenic properties of influenza virus hemagglutinin. Influenza Other Respir
Viruses. 2013;7:961–8.
18. Hashem AM, Gravel C, Farnsworth A, Zou W, Lemieux M, Xu K, et al. A novel
synthetic receptor-based immunoassay for influenza vaccine quantification.
PLoS One. 2013;8:e55428.
19. Mandenius CF, Wang R, Alden A, Bergstrom G, Thebault S, Lutsch C, et al.
Monitoring of influenza virus hemagglutinin in process samples using weak
affinity ligands and surface plasmon resonance. Anal Chim Acta.
2008;623:66–75.
20. Schmeisser F, Vasudevan A, Soto J, Kumar A, Williams O, Weir JP. A
monoclonal antibody-based immunoassay for measuring the potency of
2009 pandemic influenza H1N1 vaccines. Influenza Other Respir Viruses.
2014;8:587–95.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
